Optimizing Romosozumab for postmenopausal osteoporosis
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has gone through menopause at least 2 years ago.
- Your bone density T-score is below -2.5 at the spine, hip, or upper thigh bone.
- You have had a fracture of the spine, hip, pelvis, upper arm, or forearm in the last 3 years that happened after age 50.
- You have not taken any osteoporosis medicines (including hormone therapy) in the past 5 years.
- You do not have other bone diseases or conditions like uncontrolled thyroid problems, liver disease, severe COPD, or other disorders that affect bone metabolism.
- Your kidney function (eGFR) is 35 mL/min or higher.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two osteoporosis drugs (romosozumab and denosumab) given alone or together to see which works better for improving bone density. It may help if you are a postmenopausal woman with osteoporosis and have not taken strong bone medications recently.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This study tests a combination of two bone-building drugs (romosozumab and teriparatide) in postmenopausal women with osteoporosis who are at high risk for fractures. The goal is to see if the combination strengthens bones faster and better than either drug alone.
This study tests two injectable medications (romosozumab and abaloparatide) that help strengthen bones in women after menopause. Researchers will also look at blood markers to understand why some women respond better to treatment than others.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.